August 11, 2020

Volume X, Number 224

August 11, 2020

Subscribe to Latest Legal News and Analysis

August 10, 2020

Subscribe to Latest Legal News and Analysis

China Food & Drug Administration Releases Draft Measures On Unannounced Pharmaceutical Drug Inspections

On May 12, 2014, the China Food and Drug Administration (CFDA) released draft Measures on Unannounced Drug Inspections (draft Measures) for public comment. The comments are due on June 12, 2014. The draft Measures permit CFDA and the provincial drug regulatory authorities to conduct unannounced site inspections of drug manufacturers and distributors within their respective jurisdictions. CFDA currently has authority to conduct unannounced inspections, for example, with regard to drug Good Manufacturing Practice Violations (as well as in the food and medical device spaces), but the draft Measures are a more comprehensive framework than prior rules. The draft Measures come at a particularly important time, because CFDA is currently working on draft revisions to the Drug Administration Law (DAL),1 which would provide CFDA with an enhanced role in post-marketing supervision and enforcement. Therefore, comments on the draft Measures and any experience resulting from their ultimate implementation could influence the DAL revision process.

Under the draft Measures, the CFDA would be responsible for “organizing” unannounced inspections that reach national scope, while the provincial drug regulatory authorities would be responsible for inspections within their respective jurisdictions. The draft Measures do not make it clear what the specific division of labor would be between the CFDA and the provincial drug regulatory authorities in terms of “organizing” inspections and carrying them out. Local officials in governments below the provincial level, i.e., the county level, would be required to assist with the unannounced inspections.

The draft Measures would provide CFDA and the local authorities with fairly wide discretion to conduct these inspections. They may conduct an inspection when prompted by a complaint, product quality risks, adverse events, and when monitoring and spot-checks indicate that it is necessary to inspect. Even though CFDA and provincial drug regulatory authorities will primarily conduct the inspections, they may use the police and news media “when necessary.” It is not clear how exactly the CFDA would connect with the police or media in order to “organize” an inspection. It is possible that the Agency would use these avenues to receive information about facilities where violations may be present or to confront facilities through force or shaming. CFDA may also turn the case over to the local police if violations are tantamount to crimes.

The draft Measures require that inspections be conducted by groups of two or more inspectors, who must create an inspection plan prior to entering a facility. They must carry appropriate credentials, and must record all legal and regulatory violations discovered during the inspection with photographs or other records. They may take samples when necessary. The draft Measures state that sampling determinations and procedures must be conducted according to specific regulations on drug sampling. When urgent circumstances present themselves, such as those demanding a recall or constituting a crime, the inspectors must immediately report to the relevant drug regulatory authorities. Otherwise within three days of the inspection, or within 24 hours in urgent circumstances, the inspectors must prepare a report and present it to the relevant drug regulatory authorities.

Once the report is submitted, CFDA or the relevant local drug regulatory authority will determine what measures to take, including correction of the issues within a prescribed time, a warning letter, a consultation meeting with the inspected entity, a recall, withdrawal of the entity’s credentials, and temporary suspension of manufacturing and distribution activities. In the case of criminal violations, which is becoming one of the most common ways of punishing serious non-compliance with food and drug laws in China, the local authorities may report the case to the local police.

The draft Measures would require the inspectors to protect commercial secrets (technical and business information) during the inspections. However, some violations may result in public disclosure. Specifically, under the enforcement section of the draft Measures, officials would have wide-discretion to report on the inspection internally within government agencies, and the authorities may also report the inspection information to the public. When the results of the inspection reveal example or typical cases – which are often released in China for educational and deterrence purposes – the authorities may publicize the information via the media. In the draft Measures, this discretion appears to be unqualified.

The draft Measures would require all drug regulatory authorities to allocate a portion of their annual budget to unannounced site inspections. Expenses for inspections and sample testing would be reimbursed to manufacturers on the basis of actual costs. In other words, under the draft Measures, drug manufacturers and distributors would not be required to bear inspection costs for the authorities.

1 Although the DAL will ultimately need to be passed by China’s National People’s Congress (NPC) before it becomes law, the drafting is currently taking place within CFDA. The draft DAL will likely be distributed both internally in the government and also to the public for comment before going to the NPC.

© 2020 Covington & Burling LLPNational Law Review, Volume IV, Number 155


About this Author

Shaoyu Chen, Covington Burling Law firm, Food and Drug Practice Attorney

Shaoyu "Andrew" Chen is a partner in the firm’s Food and Drug Practice Group, and the managing director of its China Food and Drug Practice, based in the firm’s Beijing and Shanghai offices.  Mr. Chen has over a decade of experience in food and drug law, including serving in the government and the industry:

  • U.S. Food and Drug Administration (2000-2004), as Assistant Chief Counsel, based in Rockville, Maryland;
  • Amgen (2006-2010), as Senior Counsel, based in Thousand Oaks, California; and
  • GE Healthcare China (2010-2011), as Chief Compliance...
Scott Cunningham, Food and drug attorney, Covington Burling

Scott Cunningham is a member of the firm’s Food and Drug practice group.  He represents pharmaceutical, biotechnology, and medical device companies as well as trade associations in matters before the FDA, Congress, state and federal courts, and other regulatory and enforcement agencies.  Mr. Cunningham has significant experience in areas including new product development and clinical trials; IRBs; new product approvals; Hatch-Waxman exclusivities and product life-cycle management; advertising and promotion; False Claims Act and Anti-Kickback compliance issues and pharmaceutical investigations; Orphan Drug; pediatric exclusivity; manufacturing and cGMPs; import/export; controlled substances; SEC disclosure; and other aspects of federal and state regulation of pharmaceuticals, biologics, and medical devices.

John Balzano, Food and drug attorney, Covington Burling

John Balzano represents companies and business associations on U.S. and China regulatory and policy matters related to food, drugs, and other regulated products.

Mr. Balzano has over a decade of experience with legal and regulatory issues related to China, particularly with regard to products regulated by the China Food and Drug Administration and other agriculture, animal and health care products and services. He assists clients with developing strategies to obtain pre-market approvals for these products in China, including clinical development, understanding...

Richard Li, Covington, Corporate lawyer

Richard Li has wide experience in advising public and private companies and investment funds on cross-border business transactions with primary focus on life sciences industry, including mergers and acquisitions, joint ventures, strategic collaborations, licensing, co-promotion and distribution arrangements.

Mr. Li regularly advises pharmaceutical, biotechnology, medical device, food and cosmetic companies on complex regulatory and policy matters, including preclinical and clinical studies, product registration, manufacturing authorization, bidding, pricing,...